JP2001026543A - Composition for preventing and curing periodontal disease - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a safe composition for preventing and curing periodontal diseases having an excellent preventing effect on adhesion of periodontal bacteria. SOLUTION: This composition for preventing and curing periodontal diseases is characterized in containing mannose or manno-oligosaccharide. As mannose used in this invention is obtained, e.g. by decomposing a raw material containing mannan with an enzyme or an acid. As manno-oligosaccharide used in this invention, an logosaccharide in which 2-10 mannose units are bonded through αor β bonds is used.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a composition for preventing or treating periodontal disease.

[0002]

2. Description of the Related Art Periodontal disease is one of two major diseases in the oral cavity together with dental caries, and is a general term for diseases such as gingivitis and periodontitis occurring in periodontal tissues. While caries are caused by the acid produced by Gram-positive facultative anaerobic pathogens (such as Streptococcus mutans) established on the tooth surface, the enamel is demineralized, whereas periodontal disease is localized in the periodontal area. Inhabiting Polyphyromonas gingivalis (Porphyromonas)
gingivalis) is a disease that occurs in periodontal tissue due to gram-negative anaerobic pathogens, and these two diseases have completely different symptoms and causes.

Heretofore, as a means for preventing and treating such periodontal disease, it has been considered effective to use an antibiotic or an antibacterial agent to suppress the growth of the causative bacteria. However, the use of antibiotics and antibacterial agents is not preferable because it may cause side effects, the emergence of resistant bacteria, the imbalance of the indigenous flora, and the occurrence of bacterial alternation.

[0004] In addition, it is known that Polyphyromonas gingivalis, which is particularly a major causative bacterium, strongly adheres to human buccal mucosal epithelial cells.
This species is the major cause that allows the development of the gingival surface. Therefore, in order to suppress the growth of the causative bacterium in the oral cavity, it is considered important to inhibit adhesion to cells in the oral cavity.

[0005]

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for preventing or treating periodontal disease which has an excellent effect on inhibiting adhesion of periodontal disease bacteria and is safe. is there.

[0006]

Means for Solving the Problems The present inventors have made intensive studies in order to achieve the above-mentioned object, and as a result, have found that mannose and mannooligosaccharide have an excellent effect in preventing and treating periodontal disease. Heading, the present invention has been completed. That is, the gist of the present invention is a composition for preventing or treating periodontal disease, which comprises mannose or mannooligosaccharide.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail.
Mannose used in the present invention can be obtained, for example, by decomposing a raw material containing mannan with an enzyme or an acid. Further, as the manno-oligosaccharide used in the present invention, 2 to 10 mannoses are α or β
Any linked oligosaccharides may be used.
1,1, α-1,2, α-1,3, α-1,4, α-
1,6 bonds are β-1,1, β-1,
2, β-1,3, β-1,4, β-1,6 bonds. Known methods for obtaining such α-mannooligosaccharides include a method of decomposing mannan such as a cell wall of a microorganism with an enzyme or an acid, and a method of obtaining α-mannosidase from mannose by a condensation reaction. As a method for obtaining β-mannooligosaccharides, there are known methods of decomposing plant-derived mannan such as guar gum, locust bean gum, and copra meal using an enzyme or an acid, or a method of obtaining β-mannosidase from mannose by a condensation reaction. . In the present invention, mannose and mannooligosaccharide of any production method can be used, and there is no problem even if they are commercially available.

The composition for preventing or treating periodontal disease of the present invention is not particularly limited as long as it contains one or more of such mannoses. Compositions. When the mannose compound is added to foods and drinks such as sugar solutions, granules, and drops, the amount is 0.01 g or more per day, preferably 0.1 g or more.
It is desirable to add an amount that ingests at least g.

[0009] In addition, when incorporated into oral compositions such as powdered toothpaste, toothpaste, oral cavity ointments and lotions, gargles, chewing gums, etc., the amount of mannoses is 0.05 to 5.0% by weight. % Is desirable. Other compositions may be ordinary compositions.For example, in the case of a dentifrice composition, calcium carbonate, dibasic calcium phosphate, insoluble sodium metaphosphate, etc.
Sodium alginate, carrageenan, carboxymethylcellulose, silicic acid, etc. as thickeners, sorbitol, glycerin, propylene glycol, polyethylene glycol, etc. as wetting agents, other fluorinated compounds, hemostatic agents such as tranexamic acid, salt, chlorophyll, other flavors and What is necessary is just to add in combination the composition of a preservative, a bactericide, etc. suitably.

[0010]

Next, the present invention will be described in detail with reference to examples. Examples 1 to 3 and Comparative Example 1 (1) Preparation of Buccal Mucosal Epithelial Cell Suspension Buccal mucosal epithelial cells were collected from the oral cavity of a healthy adult.
Suspended in 1 M phosphate buffer (pH 6.0). Then 2
The cells were washed by repeating centrifugation at 00 × g for 5 minutes 5 times, and then washed with 0.1 M phosphate buffer (pH
6.0) and adjusted to a concentration of 1 × 10 ⁵ cells / ml.

(2) Preparation of bacterial suspension Polyphyromonas gingivalis 381 as a periodontal disease bacterium
After culturing the cells in a GAM medium at 37 ° C. for 24 hours using a strain, the cells were collected by centrifugation, and 0.1 M phosphate buffer (pH
6.0) to adjust the concentration to 1 × 10 ⁵ to 10 ⁷ cells / ml.

(3) Adhesion inhibition test of periodontal disease bacteria Bacterial mucosal epithelial cell suspension 0.5 ml prepared as described above
And 0.5 ml of the bacterial suspension were placed in a test tube, and mannose (manufactured by Funakoshi Co., Ltd .: Example 1), β-manno-oligosaccharide (β1-4 mannopentaose (Funakoshi Co., Ltd.)
Manufactured in Example 2)), α-form mannooligosaccharide (α1-3, 1
-6 mannotriose (manufactured by Funakoshi Co., Ltd .: Example 3) was added at a concentration of 0.1 mg / ml, and the mixture was incubated at 37 ° C. for 1 hour, and then 0.1 M phosphate buffer (pH 6.0). Bacteria that did not adhere to the cells were removed by repeating centrifugation at 200 xg for 5 minutes 5 times in 0). The cells were smeared on a slide glass, stained with a Safranin solution (manufactured by SIGMA), the cells were observed with a microscope, and the number of bacteria attached to the cells was counted. 10
The number of bacteria on 0 cells was counted to determine the average number of adherent bacteria per cell. For comparison, only 0.5 ml of the buccal mucosal epithelial cell suspension and 0.5 ml of the bacterial suspension were mixed,
Similarly, the average number of adherent bacteria was determined (Comparative Example 1). Table 1 shows the results.

[0013]

[Table 1]

As shown in Table 1, the addition of mannose, α-form manno-oligosaccharide or β-form manno-oligosaccharide can inhibit the adhesion of periodontal disease bacteria to the buccal mucosal epithelial cells at a high rate.

Example 4, Comparative Example 2 Toothpaste was prepared according to the formulation shown in Table 2 below according to a conventional method (Example 4). For comparison, toothpaste without mannose was prepared (Comparative Example 2).

[0016]

[Table 2]

These toothpastes were applied to patients with first-stage alveolar pyorrhea.
0 patients were used for 6 months each, and their effectiveness was determined based on redness of gingiva, disappearance of pus, improvement of blindness, improvement of tooth sway and improvement of gingiva. During the test, the patient was forced to brush this toothpaste twice in the morning and evening. The judgment was made every two months according to the following criteria. 5 points: Five items out of the above indicators were improved. 4 points: Four of the above indicators were improved. 3 points: Three of the above indicators were improved. 2 points: Two of the above indicators were improved. 1 point: One item in the index was improved. 0 point: No improvement or deterioration.

Table 3 shows the results. The values in the table are obtained by dividing the total score of each toothpaste use group on each determination day by the number of patients.

[0019]

[Table 3]

As shown in Table 3, it can be seen that the addition of mannose to toothpaste increases the effect of treating periodontal disease. In addition, there was no case where periodontal disease was deteriorated by use of the toothpaste containing mannose (Example 4), and no abnormalities in the oral cavity and uncomfortable feeling due to the use were found.

Example 5, Comparative Example 3 A troche for oral cavity was prepared according to the recipe shown in Table 4 below according to a conventional method (Example 5). Also, for comparison, α
A troche for oral cavity to which no body mannooligosaccharide was added was prepared (Comparative Example 3).

[0022]

[Table 4]

A panel test of this oral troche was carried out in the same manner as in Example 4. Table 5 shows the results. The values in the table are obtained by dividing the total score of each toothpaste use group on each determination day by the number of patients.

[0024]

[Table 5]

As shown in Table 5, it can be seen that the addition of α-manno-oligosaccharide to an oral troche increases the therapeutic effect on periodontal disease. In addition, there was no case in which periodontal disease was deteriorated by use of an oral troche (Example 5) containing α-manno-oligosaccharide, and no abnormalities in the oral cavity and uncomfortable feeling due to the use were found.

Example 6, Comparative Example 4 A mouthwash was prepared in accordance with the recipe shown in Table 6 below according to a conventional method (Example 6). Also, for comparison,
A mouse wash to which no β-manno-oligosaccharide was added was prepared (Comparative Example 4).

[0027]

[Table 6]

A panel test of this mouthwash was performed in the same manner as in Example 4. Table 7 shows the results. The values in the table are obtained by dividing the total score of each toothpaste use group on each determination day by the number of patients.

[0029]

[Table 7]

As shown in Table 7, β was added to the mouthwash.
It can be seen that the addition of body mannooligosaccharide increases the therapeutic effect of periodontal disease. In addition, there was no case in which periodontal disease was deteriorated by use of the mouthwash containing β-manno-oligosaccharide (Example 6), and no abnormalities in the oral cavity and discomfort due to the use were observed.

[0031]

Industrial Applicability The composition for preventing or treating periodontal disease of the present invention is safe and extremely effective for the prevention and treatment of periodontal disease.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat ゛ (Reference) C07H 3/04 C07H 3/04 3/06 3/06

Claims (1)

[Claims] 1. A composition for preventing or treating periodontal disease, which comprises mannose or mannooligosaccharide.